Cancer Clinical Investigation

Search results

• Belgium : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  27/10/22 → 3/11/22

  3 items of Media coverage

  Press/Media

• Lupin to acquire 2 inhalation brands from Sunovion

  Ajai Chari

  1/11/22

  1 item of Media coverage

  Press/Media

• BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

  Hanna Irie

  1/11/22

  1 item of Media coverage

  Press/Media

• Tecvayli Approved for Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  27/10/22 → 31/10/22

  2 items of Media coverage

  Press/Media

• Solawave launches 1st product outside of skin tool category

  Ajai Chari

  31/10/22

  1 item of Media coverage

  Press/Media

• Breast Cancer Research Foundation renews support for Mount Sinai Research on triple-negative breast cancer

  Hanna Irie

  31/10/22

  3 items of Media coverage

  Press/Media

• Janssen TECVAYLI gets USFDA nod for relapsed or refractory multiple myeloma

  Ajai Chari

  29/10/22

  1 item of Media coverage

  Press/Media

• FDA Approves Teclistamab-cqyv as First Bispecific T-cell Engager Antibody for Treatment of Patients With Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  26/10/22

  1 item of Media coverage

  Press/Media

• -Janssen Pharmaceutical - U.S. FDA Approves TECVAYLI, the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  26/10/22

  2 items of Media coverage

  Press/Media

• U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  26/10/22

  2 items of Media coverage

  Press/Media

• FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  26/10/22

  1 item of Media coverage

  Press/Media

• FDA Approves First Bispecific Antibody for Multiple Myeloma

  Ajai Chari

  26/10/22

  1 item of Media coverage

  Press/Media

• U.S. FDA Approves TECVAYLI (Teclistamab-Cqyv), The First Bispecific T-Cell Engager Antibody For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma'

  Ajai Chari

  25/10/22

  1 item of Media coverage

  Press/Media

• First Bispecific Antibody, Teclistamab, Now FDA Approved in Multiple Myeloma

  Ajai Chari

  25/10/22

  1 item of Media coverage

  Press/Media

• Janssen Pharmaceutical Companies of Johnson & Johnson: U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  25/10/22

  1 item of Media coverage

  Press/Media

• FDA approves Tecvayli for advanced multiple myeloma

  Ajai Chari

  25/10/22

  1 item of Media coverage

  Press/Media

• Janssen (JNJ) Announces U.S. FDA Approves TECVAYLI, the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  25/10/22

  1 item of Media coverage

  Press/Media

• U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Ajai Chari

  25/10/22

  84 items of Media coverage

  Press/Media

• Icahn School of Medicine at Mount Sinai Listed a New Clinical Trial to Study Pembrolizumab for Advanced NSCLC and PS 2-3

  Deborah Doroshow

  21/10/22

  1 item of Media coverage

  Press/Media

• US Patent Issued to Icahn School of Medicine at Mount Sinai on Oct. 18 for "Serine threonine kinase (AKT) degradation / disruption compounds and methods of use" (New York Inventors)

  Xufen Yu, Ramon Parsons & Jian Jin

  19/10/22

  1 item of Media coverage

  Press/Media

• US Patent Issued to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI on Oct. 18 for "Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy" (New York Inventors)

  Augusto Villanueva Rodriguez

  19/10/22

  1 item of Media coverage

  Press/Media

• Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis

  John Mascarenhas

  18/10/22

  1 item of Media coverage

  Press/Media

• Samir Parekh, MD, on Improving Survival in Multiple Myeloma With Sequential T-Cell Redirection Therapies

  Samir Parekh

  17/10/22

  1 item of Media coverage

  Press/Media

• Dr. Mascarenhas on the Effect of Pacritinib on Anemia in Myelofibrosis

  John Mascarenhas

  7/10/22

  1 item of Media coverage

  Press/Media

• Early detection key in management of lung disease linked to trastuzumab deruxtecan

  Charles Powell

  4/10/22

  1 item of Media coverage

  Press/Media